We can provide species identification for members of the Burkholderia cepacia complex of bacteria. We also can provide strain typing information, as well as identifications for other species which grow on Burkholderia cepacia selective agar and for which the preliminary identification might be equivocal: such as B. gladioli, Ralstonia species, Pandoraea species and others. Most of our work is for cystic fibrosis clinics, however we are very happy to provide assistance to anyone else requiring identification of these bacteria.
We employ various approaches to determine how DNA methylation and chromatin protein modifications are regulated, how they interact with the underlying genetic sequence to affect which genes are expressed in which cells, and how changes to these epigenetic marks can affect human development and lifelong health trajectories. Together, the research in our lab bridges the molecular mechanisms of epigenetic regulation and the social and environmental determinants of human health to develop a comprehensive understanding of early life.
We are systematically dissecting the molecular mechanisms of the neonatal and infant response to infection or vaccination. Based on that knowledge, we are identifying immune modulators that help protect newborns and infants.
The OPSiP study (short for "Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization") is a randomized controlled trial (RCT) that is recruiting 450 participants in Vancouver, British Columbia.
Pocket Doc for Pneumonia is a low-cost smartphone tool that uses a light-weight sensor and a data-driven app to assess a child’s vital signs and overall condition, deliver an accurate diagnosis and recommend inexpensive, life-saving treatments such as antibiotics, oxygen and fluids.
A recently released study shows asthma rates are falling thanks to efforts by physicians to avoid prescribing antibiotics to young children, except when necessary. The study shows that being prescribed antibiotics within the first 12 months of life is associated with almost double the risk of being diagnosed with asthma by age five.
Dr. Srinivas Murthy, a critical care specialist who is also trained in infectious diseases and an investigator at BC Children’s Hospital, is leading new high-quality research on COVID-19 treatment to help Canadians and people around the world.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.